SCHEMBL110395

SCHEMBL110395

CCCOc1ccc(-c2nc(-c3ccc(OC)cc3)cc(C(=O)OC)c2N)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 7/20 0.69
PDE10A Q9Y233 1/20 0.55
DHODH Q02127 1/20 0.53
PTGS2 P35354 1/20 0.47
ALPL P05186 1/20 0.47
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 5/20 0.45
GAA P10253 2/20 0.45
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2D6 P10635 1/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
MEN1 O00255 1/20 0.44
CYP3A4 P08684 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15976429 0.91 PLA2G2A (0.57) PLA2G2APDE10ADHODHKDM4EALDH1A1
SCHEMBL140353 0.90 PLA2G2A (0.64) PLA2G2AALPLKDM4EALDH1A1CYP1A2
SCHEMBL110884 0.85 PLA2G2A (0.59) PLA2G2ADHODHKDM4EALDH1A1CYP1A2
SCHEMBL110393 0.85 DHODH (0.52) PLA2G2ADHODHKDM4EALDH1A1MEN1
SCHEMBL141016 0.81 PLA2G2A (0.55) PLA2G2AALPLKDM4EALDH1A1CYP1A2
SCHEMBL108830 0.81 PLA2G2A (0.55) PLA2G2AALPLKDM4EALDH1A1CYP1A2
SCHEMBL143039 0.80 KDM4E (0.57) PLA2G2ADHODHALPLKDM4EALDH1A1
SCHEMBL141017 0.77 PLA2G2A (0.50) PLA2G2AALPLKDM4ECYP1A2CYP2C9
SCHEMBL11004661 0.74 NPC1 (0.55) PLA2G2APTGS2ALPLKDM4EALDH1A1
SCHEMBL178679 0.72 DYRK1A (0.45) PLA2G2AKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 PLA2G2A 4509/4885PDE10A 1613/4885DHODH 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.